Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 6;13(7):1083-1084.
doi: 10.2215/CJN.03180318. Epub 2018 Apr 16.

Introduction to Nephropharmacology for the Clinician: A New CJASN Series

Thomas D Nolin  1 , Mark A Perazella  2   3
Affiliations

Introduction to Nephropharmacology for the Clinician: A New CJASN Series

Thomas D Nolin et al. Clin J Am Soc Nephrol. .
No abstract available

Keywords: Acute Kidney Injury; Chronic; Drug-related Side Effects and Adverse Reactions; Humans; Pharmacodynamics; Pharmacogenetics; Pharmacology; Renal Insufficiency; United States; kidney; kidney disease; nephrology; pharmacokinetics.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Several factors affect clinical pharmacology in humans.
See this image and copyright information in PMC

References

    1. Burnier M, Pruijm M, Wuerzner G, Santschi V: Drug adherence in chronic kidney diseases and dialysis. Nephrol Dial Transplant 30: 39–44, 2015 - PubMed
    1. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R: Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 4: 1089–1096, 2009 - PMC - PubMed
    1. Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P: Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80: 1122–1137, 2011 - PubMed
    1. Coca SG, Krumholz HM, Garg AX, Parikh CR: Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 296: 1377–1384, 2006 - PubMed
    1. Konstantinidis I, Nadkarni GN, Yacoub R, Saha A, Simoes P, Parikh CR, Coca SG: Representation of patients with kidney disease in trials of cardiovascular interventions: An updated systematic review. JAMA Intern Med 176: 121–124, 2016 - PubMed